NCT00075569View on ClinicalTrials.gov

SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Cervical CancerPrecancerous Condition
Interventions
BIOLOGICAL

HspE7

500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.

Trial Locations (2)

10021

New York Weill Cornell Cancer Center at Cornell University, New York

10461

Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Albert Einstein College of Medicine

OTHER

NCT00075569 - SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia | Biotech Hunter | Biotech Hunter